Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Göran Duker"'
Autor:
Monika Sundqvist, Göran Duker, Ola Fjellström, Yu-ki Iwasaki, Fabrizio Giordanetto, Qing-Dong Wang, Takeshi Kato, Anita Wallin, Stanley Nattel
Publikováno v:
Journal of Cardiovascular Electrophysiology. 25:531-536
Effects of T-Type Calcium Channel Blockade on AFBackground The T-type Ca2+ channel (ICaT) blocker mibefradil prevents AF-promoting remodeling occurring with atrial tachycardia, an action that has been attributed to ICaT inhibition. However, mibefradi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82b2d4641252de571e74fc27a54cd0f2
https://doi.org/10.1111/jce.12346
https://doi.org/10.1111/jce.12346
Autor:
M A Vos, Lukas Nalos, Marcel A.G. van der Heyden, Maaike Peschar, M. Houtman, R. van der Nagel, T.P. de Boer, Göran Duker, Martin B. Rook, Rosanne Varkevisser, Jet D.M. Beekman, Morten B. Thomsen, Peter Sartipy, Mkb Jonsson, Tab Van Veen
Publikováno v:
British Journal of Pharmacology. 165:467-478
BACKGROUND AND PURPOSE Drug development requires the testing of new chemical entities for adverse effects. For cardiac safety screening, improved assays are urgently needed. Isolated adult cardiomyocytes (CM) and human embryonic stem cell-derived car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29ec3594e46a5edc9cb8ab49e9cc5c56
https://doi.org/10.1111/j.1476-5381.2011.01558.x
https://doi.org/10.1111/j.1476-5381.2011.01558.x
Autor:
Antonio Llinas, Fredrik Thorstensson, Emma Lindhardt, Ågot Högberg, Kristina Nilsson, Anders Lindqvist, Annika Åstrand, Göran Duker, Victoria Ullah, Gavin O'Mahony, Qing-Dong Wang, Pernilla Ståhlberg, Nidhal Selmi, Laurent Knerr, Fabrizio Giordanetto
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:5557-5561
Chemical evolution of a HTS-based fragment hit resulted in the identification of N -(1-adamantyl)-2-[4-(2-tetrahydropyran-4-ylethyl)piperazin-1-yl]acetamide, a novel, selective T-type calcium channel (Ca v 3.2) inhibitor with in vivo antihypertensive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cba3b145e5adacb5094a5344ec69713
https://doi.org/10.1016/j.bmcl.2011.06.092
https://doi.org/10.1016/j.bmcl.2011.06.092
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 63:40-46
Accumulating evidence suggest that drug-induced QT prolongation per se poorly predicts repolarisation-related proarrhythmia liability. We examined whether beat-by-beat variability of the QT interval may be a complementary proarrhythmia marker to QT p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a561f54ef1f14625e695a9933d7cab45
https://doi.org/10.1016/j.vascn.2010.04.010
https://doi.org/10.1016/j.vascn.2010.04.010
Publikováno v:
Trends in Pharmacological Sciences. 31:364-371
Atrial fibrillation (AF) is an arrhythmia of growing clinical concern that is increasing in prevalence and is associated with significant morbidity and mortality. Pharmacological agents remain the first-line therapy for the AF patient, and the potent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf0207567a5f668d031ba905c00a8f2
https://doi.org/10.1016/j.tips.2010.05.001
https://doi.org/10.1016/j.tips.2010.05.001
Autor:
Carl-Fredrik Mandenius, Giorgio Minotti, Tina C. Stummann, Y. Jean Pierre Valentin, Robin L. Jones, J. Magnus Fredriksson, Thomas Meyer, Marina Hasiwa, Göran Duker, Y. James Kang, Mario Beilmann, Bernd J. Zünkler, Susanne Bremer, Berengere Dumotier
Publikováno v:
Cardiovascular Toxicology. 9:107-125
Cardiotoxicity is among the leading reasons for drug attrition and is therefore a core subject in non-clinical and clinical safety testing of new drugs. European Centre for the Validation of Alternative Methods held in March 2008 a workshop on “Alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a202da502ab43233d90ace4b429a4005
https://doi.org/10.1007/s12012-009-9045-3
https://doi.org/10.1007/s12012-009-9045-3
Autor:
Malin K.B. Jonsson, Marie-José Goumans, Toon A.B. van Veen, Marc A. Vos, Göran Duker, Peter Sartipy
Publikováno v:
Expert Opinion on Drug Discovery. 4:357-372
The pharmaceutical industry suffers from high attrition rates during late phases of drug development. Improved models for early evaluation of drug efficacy and safety are needed to address this problem. Recent developments have illustrated that human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ae3c6f88b64b0ebed1a6860e015a19e
https://doi.org/10.1517/17460440902794912
https://doi.org/10.1517/17460440902794912
Autor:
Anna H. Persson, Sandra A.G. Visser, Lars B. Nilsson, Tomas Forsberg, Johan Gabrielsson, Anna Ollerstam, Jan-Arne Björkman, Ahmad Al-Saffar, Göran Duker
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 56:131-144
Introduction: The aim of the present study was to compare sensitivity in detecting the drug-induced QT interval prolongation in three dog models: conscious telemetered at sinus rhythm and conscious and anesthetized dogs during atrial pacing. The test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c4b2dc8c425cc9af7b025790a455bb1
https://doi.org/10.1016/j.vascn.2007.05.002
https://doi.org/10.1016/j.vascn.2007.05.002
Autor:
Lars B. Nilsson, Göran Eklund, Stig Johan Wiklund, Göran Duker, Ahmad Al-Saffar, Tomas Forsberg, Johan Gabrielsson, Anna H. Persson, Anna Ollerstam, J. Magnus Fredriksson, Sandra A.G. Visser
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 55:35-48
Introduction: Drug-induced QT interval prolongation may lead to ventricular arrhythmias. The aim of the study was to optimize QT interval data processing to quantify drug-induced QT interval prolongation in the telemetry instrumented conscious dog mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea178a75325028559170c347f76cfad
https://doi.org/10.1016/j.vascn.2006.02.009
https://doi.org/10.1016/j.vascn.2006.02.009
Publikováno v:
Journal of Cardiovascular Pharmacology. 46:7-17
AZD7009 is a novel antiarrhythmic compound in early clinical development for management of atrial fibrillation. Electrophysiological studies in animals have shown high antiarrhythmic efficacy, predominant action on atrial electrophysiology, and low p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57ab282dca1414c464bc3da5369a7864
https://doi.org/10.1097/01.fjc.0000161405.37198.c1
https://doi.org/10.1097/01.fjc.0000161405.37198.c1